Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: A pilot study

Psychopharmacology Bulletin

Volumn 43, Issue 3, 2010, Pages 37-44

  Lahti, Tuuli ^a   Halme, Jukka T ^a   Pankakoski, Maiju ^a   Sinclair, David ^a   Alho, Hannu ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

DSM IV; Naltrexone; Pathological gambling; PG YBOCS; SOGS

Indexed keywords

NALTREXONE; NALOXONE; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; MALE; PATHOLOGICAL GAMBLING; QUALITY OF LIFE; THERAPY EFFECT; AGED; CLINICAL TRIAL; DEPRESSION; FINLAND; MIDDLE AGED; MOTIVATION; MULTIMODALITY CANCER THERAPY; PILOT STUDY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOTHERAPY; QUESTIONNAIRE; TREATMENT OUTCOME;

ADULT; AGED; COMBINED MODALITY THERAPY; DEPRESSION; FEMALE; FINLAND; GAMBLING; HUMANS; MALE; MIDDLE AGED; MOTIVATION; NALOXONE; NARCOTIC ANTAGONISTS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY, BRIEF; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953022272     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Shaffer HJ, Hall MN, Vander Bilt J. Estimating the prevalence of disordered gambling behavior in the united states and canada: A research synthesis. American Journal of Public Health. 1999;89(9): 1369-1376. (Pubitemid 29404561)
2. Aho P, Turja T. Suomalaisten rahapelaaminen. Helsinki, Finland: Taloustutkimus Oy ja Sosiaali- ja terveysministeriö 2007.
3. Gooding P, Tarrier N. A systematic review and meta-analysis of cognitive-behavioural interventions to reduce problem gambling: Hedging our bets? Behaviour Research and Therapy. 2009;47(7):592-607.
4. Leung KS, Cottler LB. Treatment of pathological gambling. Current Opinion in Psychiatry. 2009;22(1):69-74.
5. Petry NM, Weinstock J, Morasco BJ, Ledgerwood DM. Brief motivational interventions for college student problem gamblers. Addiction (Abingdon, England). 2009;104(9):1569-1578.
6. Petry NM, Weinstock J, Ledgerwood DM, Morasco B. A randomized trial of brief interventions for problem and pathological gamblers. Journal of Consulting and Clinical Psychology. 2008;76(2):318-328. (Pubitemid 351522265)
7. Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. The Journal of Clinical Psychiatry. 2008; 69(5):783-789. (Pubitemid 351838687)
8. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: A pilot study. Biological Psychiatry. 2007;62(6):652-657. (Pubitemid 47314380)
9. Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: A multi-centre randomized controlled trial. International Clinical Psychopharmacology. 2003;18(4):243-249. (Pubitemid 36871876)
10. McElroy SL, Nelson EB,Welge JA, Kaehler L, Keck PEJ. Olanzapine in the treatment of pathological gambling: A negative randomized placebo-controlled trial. The Journal of Clinical Psychiatry. 2008; 69(3):433-440. (Pubitemid 351549397)
11. Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli R. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. The Journal of Clinical Psychiatry. 2002;63(6):501-507. (Pubitemid 34680358)
12. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biological Psychiatry. 2001;49(11):914-921. (Pubitemid 32493813)
13. Blanco C, Petkova E, Ibanez A, Saiz-Ruiz J. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists. 2002;14(1):9-15. (Pubitemid 34538827)
14. Dannon PN, Lowengrub K, Gonopolski Y, Musin E, Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: A randomized, blind-rater comparison study. Clinical Neuropharmacology. 2005;28(1):6-10. (Pubitemid 40269711)
15. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: A randomized single-blind study. The Journal of Clinical Psychiatry. 2002;63(7):559-564. (Pubitemid 34787319)
16. Spanagel R, Herz A, Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proceedings of the National Academy of Sciences of the United States of America. 1992;89(6):2046-2050.
17. Pallesen S, Molde H, Arnestad HM, et al. Outcome of pharmacological treatments of pathological gambling: A review and meta-analysis. Journal of Clinical Psychopharmacology. 2007;27(4):357-364. (Pubitemid 47075506)
18. Karhuvaara S, Simojoki K, Virta A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: A randomized double-blind placebo-controlled multicenter study. Alcoholism, Clinical and Experimental Research. 2007;31(7):1179-1187. (Pubitemid 46934385)
19. Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: A factorial double-blind, placebocontrolled trial. Journal of Clinical Psychopharmacology. 2001;21(3):287-292. (Pubitemid 32452933)
20. Lesieur HR, Blume SB. The south oaks gambling screen (SOGS): A new instrument for the identification of pathological gamblers. The American Journal of Psychiatry. 1987;144(9):1184-1188. (Pubitemid 17147523)
21. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th edition). Washington DC, United States: American Psychiatric Association 1994.
22. Goodman WK, Price LH, Rasmussen SA, et al. The yale-brown obsessive compulsive scale. I. development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011. (Pubitemid 19278229)
23. The EuroQol Group. EuroQol-a new facility for the measurement of health-related qualiy 1990.
24. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry. 1961;4:561-571.
25. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro M. AUDIT-the Alcohol Use Disorder Identification Test: guidelines for use in primary health care; 2001. WHO, Geneva, Switzerland.
26. Little RJ, Rubin DB. (Eds.). Statistical analysis with missing data. (1st ed.). New York: John Wiley 1987.
27. Pinheiro J, Bates D, DebRoy D, Sarkar D. the R Core team. Linear and nonlinear mixed effects models. New York, United States 2009.
28. Laird NM, Ware JH. Random-effects models for longitudinal data. 1982;38(4)(Biometrics):963-974.
29. R Development Core Team (2009). R: A language and environment for statistical computing. R foundation for statistical computing. http://www.R-project.org